Smart & Biggar uncovers and maximizes intellectual property and technology assets for our clients.
Today’s fast-paced innovation economy demands a higher level of expertise and attention to detail when it comes to IP strategy and protection. With over 125 lawyers, patent agents and trademark agents collaborating across five Canadian offices, Smart & Biggar is trusted by the world’s leading innovators to find value in their IP rights.
As market leaders in IP, Smart & Biggar’s team is on the pulse when it comes to the latest developments and the wider industry changes that impact our clients. To stay informed, visit smartbiggar.ca/insights, including access to our RxIP Update (smartbiggar.ca/insights/rx-ip-updates), a monthly digest of the latest decisions and law surrounding the life sciences and pharmaceutical industries.
To print this article, all you need is to be registered or login on Mondaq.com.
On December 21, 2020, the Certificate of Supplementary Protection
Regulations were amended to add the United Kingdom as a
"prescribed country" for the purpose of determining the
timeliness of the Certificate of Supplementary Protection (CSP)
applicant's New Drug Submission. The amendment was a
consequence of Brexit; the U.K. was previously a prescribed country
as a member of the European Union. The amendment came into force on
January 6, 2021, and the CSP Guidance Document and Application Form were updated accordingly as
of that date.
The preceding is intended as a timely update on Canadian
intellectual property and technology law. The content is
informational only and does not constitute legal or professional
advice. To obtain such advice, please communicate with our offices
directly.
